Akums Drugs & Pharma
add_icon

Akums Drugs & Pharma

431.80
+3.05
(0.71%)
Market Cap
6,796.27 Cr
PE Ratio
20.92
Volume
438.00
Day High - Low
433.60 - 415.00
52W High-Low
622.95 - 405.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
6,796.27 Cr
EPS
22.60
PE Ratio
20.92
PB Ratio
2.15
Book Value
200.11
EBITDA
516.60
Dividend Yield
0.00 %
Industry
Healthcare
Return on Equity
11.22
Debt to Equity
0.17
Analyst Rating and Forecast
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
positive
Akums Drugs and Pharmaceuticals Limited secured European GMP certificates for its Plant 1 and Plant 2 facilities at Haridwar, enabling access to EU regulated markets and new business opportunities.
neutral
Ruby Qc Investment Holdings Pte Ltd disposed of 72.79 lakh equity shares representing 4.62% stake in Akums Drugs and Pharmaceuticals Limited through block deal on December 22, 2025.
negative
Maxcure Nutravedics Limited, wholly-owned subsidiary of Akums Drugs & Pharmaceuticals, receives additional penalty of ₹1.80 crores from Gujarat State Tax authorities for shipping address errors in invoices.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,639.90
#1 3,93,466.94
37.51
#1 54,729.00
9.71
#1 10,980
2.89
32.48
6,100.00
1,61,935.83
64.72
9,712.00
18.67
2,191
35.10
31.96
3,944.60
1,33,503.19
63.25
11,539.40
6.99
1,911
30.46
51.26
1,313.00
1,06,060.44
23.39
28,409.50
7.12
5,291
-57.18
16.66
1,238.00
1,03,327.24
18.74
33,741.20
16.73
5,725
-15.28
53.53
2,154.90
98,435.57
22.57
22,909.50
13.74
3,306
#1 72.75
49.85
892.50
89,806.38
#1 17.88
23,511.00
18.55
4,615
34.60
39.82
2,106.60
86,961.52
48.74
12,744.20
#1 20.90
2,007
-21.05
41.23
5,748.50
68,731.94
28.55
13,458.30
3.70
2,216
10.98
54.24
1,133.10
65,810.63
19.19
32,345.60
9.43
3,484
3.81
37.32
Growth Rate
Revenue Growth
-0.99 %
Net Income Growth
42,875.00 %
Cash Flow Change
-6.64 %
ROE
10,100.00 %
ROCE
5,030.43 %
EBITDA Margin (Avg.)
232.17 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
978
1,188
1,093
955
1,026
1,050
1,030
1,081
1,051
1,050
Expenses
1,095
1,057
989
941
891
912
889
962
895
923
EBITDA
-117
131
103
14
135
138
141
120
156
127
Operating Profit %
-13 %
11 %
9 %
0 %
13 %
12 %
12 %
9 %
13 %
9 %
Depreciation
30
30
32
34
34
35
45
40
37
38
Interest
12
14
12
12
13
12
5
5
23
23
Profit Before Tax
-159
87
59
-33
88
92
91
75
96
66
Tax
29
54
-136
7
26
25
25
-75
31
23
Net Profit
-187
33
195
-40
61
67
66
150
65
43
EPS in ₹
-13.16
2.22
13.21
-2.89
4.21
4.37
4.26
9.64
4.15
2.66

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
Total Assets
2,078
2,192
3,069
3,267
3,516
4,113
Fixed Assets
645
834
1,021
1,097
1,191
1,397
Current Assets
1,250
1,157
1,864
1,879
1,941
2,275
Capital Work in Progress
57
87
31
103
195
163
Investments
6
19
0
0
0
0
Other Assets
1,371
1,252
2,017
2,066
2,130
2,553
Total Liabilities
2,078
2,192
3,069
3,267
3,516
4,113
Current Liabilities
730
580
1,272
1,266
1,211
894
Non Current Liabilities
627
725
1,172
1,278
1,585
156
Total Equity
721
887
625
723
721
3,064
Reserve & Surplus
721
884
608
689
681
3,016
Share Capital
1
1
14
29
29
31

Cash Flow

Cash Flow
2015
2016
2020
2021
2022
2023
2024
2025
Net Cash Flow
-11
4
71
-70
33
-4
59
-10
Investing Activities
-150
-123
-190
-109
-235
-305
-331
-548
Operating Activities
72
89
28
135
32
177
498
465
Financing Activities
66
37
233
-95
236
125
-108
73

Share Holding

% Holding
Feb 2024
Aug 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
84.91 %
75.26 %
75.26 %
75.26 %
75.26 %
75.26 %
75.26 %
75.26 %
FIIs
0.00 %
5.32 %
7.34 %
6.36 %
5.77 %
4.24 %
2.28 %
1.15 %
DIIs
0.00 %
7.60 %
7.52 %
7.00 %
7.40 %
8.85 %
9.28 %
14.40 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
4.43 %
2.11 %
3.33 %
3.41 %
3.60 %
5.01 %
5.51 %
Others
15.09 %
7.38 %
7.77 %
8.05 %
8.16 %
8.05 %
8.18 %
3.68 %
No of Share Holders
8
1,38,205
57,531
68,410
69,366
69,424
75,365
76,869

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
09 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
09 Nov 2024 845.30 796.60
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 566.55 570.30
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 May 2025 546.50 566.05
18 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
18 Jul 2025 566.05 559.90
08 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 Aug 2025 513.90 490.80
13 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Nov 2025 454.45 453.15

Announcements

EU-GMP Certification4 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2026
Resignation Of Senior Management PersonnelDec 27, 2025
Closure of Trading WindowDec 27, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Dec 22, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Dec 22, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - UpdateDec 16, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Dec 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 17, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 17, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2025
UpdateNov 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 13, 2025
Outcome Of Board MeetingNov 13, 2025
Board Meeting Outcome for Outcome Of Board MeetingNov 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 10, 2025
Board Meeting Intimation for Consider And Approve The Un-Audited (Standalone & Consolidated) Financial Results For The Quarter And Half Year Ended On 30Th September 2025Nov 08, 2025
Grant Of PatentNov 03, 2025
Incorporation Of Wholly Owned Subsidiary In MaltaOct 20, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Incorporation Of Joint Venture CompanyOct 13, 2025
Resignation Of Senior Management PersonnelOct 10, 2025
Closure of Trading WindowSep 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 26, 2025
Execution Of Framework Agreement With Government Of The Republic Of ZambiaAug 22, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 18, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Board Comments On Fine Levied By The ExchangeAug 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 08, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 08, 2025
Outcome Along With ResultsAug 08, 2025
Board Meeting Outcome for Outcome Of Board MeetingAug 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Board Meeting Intimation for Approval Of Un-Audited (Standalone & Consolidated) Financial Results For The Quarter Ended On 30Th June 2025.Aug 04, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 19, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMJul 18, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Resignation Of Senior Management PersonnelJul 05, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 25, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jun 24, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.06%
476
0.00%
0.00%
DSP Nifty Smallcap 250 Index Fund Direct - Growth
0.06%
105
0.06%
0.06%
Navi Nifty MidSmallcap 400 Index Fund Direct - Growth
0.02%
52
0.02%
0.02%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.01%
2
0.00%
0.00%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.06%
0
0.00%
0.00%
SBI Healthcare Opportunities Fund Direct Plan-Growth
0.00%
0
0.00%
0.00%
Angel One Nifty Total Market Index Fund Direct - Growth
0.01%
0
0.00%
0.00%
Axis Nifty 500 Index Fund Direct-Growth
0.01%
0
0.00%
0.00%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.09%
0
0.00%
0.01%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.06%
0
0.00%
0.00%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.01%
0
0.00%
0.00%
Bandhan Small Cap Fund Direct-Growth
0.42%
0
0.00%
0.01%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.06%
0
0.00%
0.00%
Edelweiss Recently Listed IPO Fund Direct-Growth
0.00%
0
0.00%
0.00%
Franklin India Multi Cap Fund Direct-Growth
1.08%
0
0.00%
0.09%
Franklin India Opportunities Direct Fund-Growth
1.37%
0
0.00%
0.00%
Franklin India Small Cap Fund Direct-Growth
0.76%
0
0.00%
0.00%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.06%
0
0.00%
0.00%
Groww Nifty Total Market Index Fund Direct - Growth
0.01%
0
0.00%
0.00%
Groww Value Fund Direct-Growth
0.00%
0
0.00%
0.00%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.06%
0
0.00%
0.00%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.02%
0
0.00%
0.01%
ICICI Prudential ELSS Tax Saver Direct Plan - Growth
0.53%
0
0.00%
0.53%
ICICI Prudential Equity & Debt Fund Direct-Growth
0.10%
0
0.00%
0.10%

Technical Indicators

RSI(14)
Neutral
39.62
ATR(14)
Less Volatile
11.04
STOCH(9,6)
Neutral
24.40
STOCH RSI(14)
Oversold
7.81
MACD(12,26)
Bearish
-3.40
ADX(14)
Strong Trend
28.90
UO(9)
Bearish
40.88
ROC(12)
Downtrend And Accelerating
-4.50
WillR(14)
Neutral
-68.17

About Akums Drugs & Pharma

Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) established in 2004. The company offers a wide range of pharmaceutical products and services both domestically and internationally. Their operations include manufacturing of Active Pharmaceutical Ingredients (APIs), sale of branded pharmaceutical formulations, formulation research and...more
Listing Date
06 Aug, 2024(1 Years, 53 days)